PhaseBio reveals Phase 2a study results for PB2452 in older patients
Category: #health  By Pankaj Singh  Date: 2019-06-19
  • share
  • Twitter
  • Facebook
  • LinkedIn

PhaseBio reveals Phase 2a study results for PB2452 in older patients

The new data is consistent with the formally published Phase 1 trial data of younger subjects treated with ticagrelor alone

PhaseBio Pharmaceutical Inc., a clinical stage biopharmaceutical company that focuses on developing and commercializing novel therapies for orphan diseases, recently announced the positive preliminary data for PB2452 from the Phase 2a clinical trial, which is its first trial that includes both older (ages 50-64) and elderly (ages 65-80) patients on dual antiplatelet therapy of low-dose aspirin and ticagrelor.

Apparently, the trial subjects resemble the patient population who are more likely to be treated with ticagrelor and if approved, probably benefit from PB2452. The trial witnessed statistically important reversal of ticagrelor 5 minutes within the initiation of PB2452 infusion and it sustained for more than 20 hours. Within 15 minutes of PB2452 infusion, platelet function was normalized, and it remained so for more than 20 hours.

Reportedly, PB2452 has seemingly tolerated the Phase 2a trial well till date, with only minor adverse events being reported. PhaseBio’s formerly published Phase 1 trials showed results similar to these new data, the trial of which was conducted in healthy younger volunteers who were treated with no aspirin but ticagrelor alone. 

There were three assays in the Phase 1 trial to measure its efficacy and the same were used to measure the efficacy of PB2452 during Phase 2a trial, with results demonstrating high correlation from all three assays in both the trials.

John Lee, M.D., Ph.D., PhaseBio’s Chief Medical Officer, said that at present, it is recommended the patients who take antiplatelet therapies like ticagrelor stop their regimen for minimum 5 days before the supposed surgery to avoid the risk of major bleeding. This is not an option for patients who require an emergency or urgent surgery.

There are no methods to reverse the antiplatelet agents’ effects for patients who are experiencing major bleeding. The approval of PB2452 could address the unmet medical needs by having the safety profile of ticagrelor enhanced. It has the potential to become the sole antiplatelet therapy with a specific reversal agent to be on the market, Lee added.

 

Source Credit- https://investors.phasebio.com/news-releases/news-release-details/phasebio-announces-positive-preliminary-results-phase-2a



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...